These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38799523)

  • 1. Correction to "The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report".
    Clin Case Rep; 2024 Jun; 12(6):e8961. PubMed ID: 38799523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual orexin receptor antagonist suvorexant in alcohol use disorder and comorbid insomnia: A case report.
    Campbell EJ; Bonomo Y; Collins L; Norman A; O'Neill H; Streitberg A; Galloway K; Kyoong A; Perkins A; Pastor A; Lawrence AJ
    Clin Case Rep; 2024 May; 12(5):e8740. PubMed ID: 38698873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suvorexant to treat alcohol use disorder and comorbid insomnia: Plan for a phase II trial.
    Campbell EJ; Norman A; Bonomo Y; Lawrence AJ
    Brain Res; 2020 Feb; 1728():146597. PubMed ID: 31837287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
    Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H
    Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant.
    Norman JL; Anderson SL
    Nat Sci Sleep; 2016; 8():239-47. PubMed ID: 27471419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant.
    Khazaie H; Sadeghi M; Khazaie S; Hirshkowitz M; Sharafkhaneh A
    Front Psychiatry; 2022; 13():1070522. PubMed ID: 36578296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia.
    Han AH; Burroughs CR; Falgoust EP; Hasoon J; Hunt G; Kakazu J; Lee T; Kaye AM; Kaye AD; Ganti L
    Health Psychol Res; 2022; 10(5):67898. PubMed ID: 36726477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orexin Receptor Antagonists and Insomnia.
    Wu X; Xue T; Chen Z; Wang Z; Chen G
    Curr Psychiatry Rep; 2022 Oct; 24(10):509-521. PubMed ID: 35972717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.
    Owen RT
    Drugs Today (Barc); 2016 Jan; 52(1):29-40. PubMed ID: 26937493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.
    Ma J; Svetnik V; Snyder E; Lines C; Roth T; Herring WJ
    Sleep; 2014 Oct; 37(10):1609-19. PubMed ID: 25197807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sleeping giant: Suvorexant for the treatment of alcohol use disorder?
    Campbell EJ; Marchant NJ; Lawrence AJ
    Brain Res; 2020 Mar; 1731():145902. PubMed ID: 30081035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suvorexant: first global approval.
    Yang LP
    Drugs; 2014 Oct; 74(15):1817-22. PubMed ID: 25227290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suvorexant: The first orexin receptor antagonist to treat insomnia.
    Dubey AK; Handu SS; Mediratta PK
    J Pharmacol Pharmacother; 2015; 6(2):118-21. PubMed ID: 25969666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine.
    Gentile TA; Simmons SJ; Barker DJ; Shaw JK; España RA; Muschamp JW
    Addict Biol; 2018 Jan; 23(1):247-255. PubMed ID: 28419646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suvorexant, a dual orexin receptor antagonist for the management of insomnia.
    Bennett T; Bray D; Neville MW
    P T; 2014 Apr; 39(4):264-6. PubMed ID: 24757363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suvorexant in insomnia: efficacy, safety and place in therapy.
    Rhyne DN; Anderson SL
    Ther Adv Drug Saf; 2015 Oct; 6(5):189-95. PubMed ID: 26478806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo.
    Roehrs T; Withrow D; Koshorek G; Verkler J; Bazan L; Roth T
    J Clin Sleep Med; 2020 Mar; 16(3):415-421. PubMed ID: 31992394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
    Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N
    Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suvorexant in the Treatment of Difficulty Falling and Staying Asleep (Insomnia).
    Berger AA; Sottosanti ER; Winnick A; Keefe J; Gilbert E; Hasoon J; Thase ME; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2022 Feb; 52(1):68-90. PubMed ID: 35342199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.